1 / 27

Mylan Pharmaceuticals: The Legal Drug Pushers

Overview. Strategic Analysis of Mylan Laboratories Inc.. Introduction Issues and Outlook Profile Present Strategies 3 Strategic Strategies Recommendations Action Plan . Introduction. Strategic Analysis of Mylan Laboratories Inc.. Mylan Laboratories Inc. was incorporated in 1970

hazel
Download Presentation

Mylan Pharmaceuticals: The Legal Drug Pushers

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Mylan Pharmaceuticals: The Legal Drug Pushers Matthew Bell Betsy Lewis Frederick Ryan Ford Gaurav Walawalkar

    2. Overview Strategic Analysis of Mylan Laboratories Inc.

    3. Introduction Strategic Analysis of Mylan Laboratories Inc. Introduce Group! Mylan Laboratories Inc. is the third-largest generic pharmaceutical company in the world, by marketing more than 570 products to consumers in more than 90 countries. The Company was incorporated in Pennsylvania in 1970. They develop, license, manufacture, market, and distribute generic, brand, and branded generic pharmaceutical products. They hold top-five positions in 13 different established markets worldwide. Introduce Group! Mylan Laboratories Inc. is the third-largest generic pharmaceutical company in the world, by marketing more than 570 products to consumers in more than 90 countries. The Company was incorporated in Pennsylvania in 1970. They develop, license, manufacture, market, and distribute generic, brand, and branded generic pharmaceutical products. They hold top-five positions in 13 different established markets worldwide.

    4. Issues and Outlook Profile Strategic Analysis of Mylan Laboratories Inc.

    5. Issues and Outlook Profile Strategic Analysis of Mylan Laboratories Inc.

    6. Issues and Outlook Profile Strategic Analysis of Mylan Laboratories Inc.

    8. Issues and Outlook Profile Strategic Analysis of Mylan Laboratories Inc.

    10. Strategy Options Strategic Analysis of Mylan Laboratories Inc. Placing great emphasis on non-prescription drug sales growth in India, Russia, and China, where economic growth is faster. Also, looking to sell more consumer healthcare products in emerging regions, specifically India, where many consumers buy their medicines over the counter.Placing great emphasis on non-prescription drug sales growth in India, Russia, and China, where economic growth is faster. Also, looking to sell more consumer healthcare products in emerging regions, specifically India, where many consumers buy their medicines over the counter.

    12. Present Strategies Strategic Analysis of Mylan Laboratories Inc.

    14. Diversification Mylan acquired Dey LP, a specialty branded pharma division, for $6.7 billion. “Mylan took a detour from its core business last year when it bought Dey LP, a specialty branded pharmaceutical division. Unfortunately, this operation didn’t perform up to par, specifically because of poor sales of mainstay drug.”(Jeremy Butler,2008)

    15. Suggested Strategies Strategic Analysis of Mylan Laboratories Inc.

    16. Market Development Facts The US accounts for over half of the $6OObillion plus global pharmaceutical market. Of this, the global generic drugs market is about $6O billion and the US accounts for over half of this market as well. (http://www.thehindubusinessline.com,2006) It is estimated that 41.2 million Americans or 14.6 percent of the U.S. population have no medical insurance and lack access to health benefits such as prescription drugs (http://wistechnology.com,2006)

    17. Market Development Cont. Strategic Analysis of Mylan Laboratories Inc.

    18. Focus Strategy Focus Strategy Towards Geriatric Pharmaceuticals US. Census Bureau (2006) An estimated 78.2 million baby boomers as of July 1, 2005 People turning 60 everyday in 2006 would be around 7,918 “It is estimated that between 30% and 40% of pharmaceutical products are used by people over the age of 65” (Middleton, 1999).

    19. Focus Strategy Areas of Importance of Geriatric Pharmaceuticals Alzheimer’s Muscle Loss and Wasting Hip Fractures Appetite Enhancers Urinary Incontinence Sleep Disturbances

    20. Focus Strategy A Large Piece of the Pie Between 1995 and 1999 U.S. spending on pharmaceutical drugs doubled $65 Billion to $125 Billion Government study shows to be at around $243 Billion in 2008 with the baby boomers coming senior citizens

    21. Focus Strategy The time is now with the first baby boomers turning 60 in 2006 The need for medicine for the elderly will be in much larger demand than before There will be fierce competition, but can differentiate with lower costs in generic drugs The amount of money that will be spent on medicine for the elderly is much to large to pass up

    22. Recommendation Strategic Analysis of Mylan Laboratories Inc.

    23. Action Plan Strategic Analysis of Mylan Laboratories Inc.

    24. Questions Strategic Analysis of Mylan Laboratories Inc.

    25. References Strategic Analysis of Mylan Laboratories Inc.

More Related